Yuesai Bio Secures Nearly RMB 100 Million Series A+ Strategic Financing to Advance Pipeline Development and File IPO Prospectus

Recently,Shanghai State-owned Capital Investment Guidance Fund (SSCILF) and the Leading Zone Fund under Shanghai Pudong Venture Investment Co., Ltd. jointly completed the Series A+ strategic financing of Shanghai UniXelI Biotechnology Co., Ltd. (“UniXelI Biotech”).The financing proceeds will be used to accelerate the advancement of the company’s pipeline and clinical trials, further deepening the large-scale development and industrialization of innovative cell therapy drugs.

Since its establishment in 2021, UniXelI BIOTECHNOLOGY has been dedicated to developing next-generation cell therapy drugs based on human pluripotent stem cell technology. The company has successfully created an innovative, independently developed technical platform for pluripotent stem cell-derived therapeutics, achieving full-cycle coverage from research and development to clinical trial application. Multiple R&D achievements have been published in top international academic journals such as *Cell Stem Cell*. The company’s pipeline in development coversNeurological Disorders Such as Parkinson's Disease and EpilepsyAmong these, UX-DA001 has become the first Parkinson’s disease autologous cell therapy project worldwide to achieve dual regulatory submissions in China and the United States and obtain approval for new drug clinical trials, while also receiving Fast Track designation from the U.S. Food and Drug Administration (FDA). Currently, this product is undergoing a Phase I registrational clinical trial at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. As of recently, cell transplantation has been completed in multiple subjects. Follow-up data have demonstrated favorable safety and tolerability profiles, with positive preliminary efficacy signals observed, laying a solid foundation for the advancement of subsequent clinical development.

Shanghai State-owned Investment Guide Biomedical Industry Fund of Funds stated: This investment marks the Shanghai State-owned Capital Investment Leading Biopharmaceutical Industry Fund of Funds' entry into the cell therapy sector.First direct investment project,It is our key strategic move in the frontier sector, demonstratingSynergistic Collaboration Between Municipal and District-Level Capital. We have always adhered to"Invest early, invest small, invest in hard tech, and invest for the long term"philosophy of supporting original, source-level innovation. UniXelI BIOTECHNOLOGY’s iPSC differentiation process is industry-leading, and its iPSC-derived cell therapy for Parkinson’s disease has demonstrated significant clinical value. We aim to leverage capital support to accelerate the enhancement of Shanghai’s global competitiveness in the field of cell and gene therapy. In the future, we will continue to harness the strengths of state-owned capitalThe Role of Strategic Guidance and Patient Capital, with long-term deep engagement in the CGT sector, supporting the growth of innovative enterprises such as UniXelI BIOTECHNOLOGY, and driving Shanghai’s leap from “technological breakthroughs to industrial clusters, and product innovation to ecosystem leadership,” thereby making more domestically produced innovative drugs accessible to patients and contributing “Shanghai’s strength” to the high-quality development of the biopharmaceutical industry.

Pudong Venture Capital Group’s Leading Zone Fund Discusses Investment in UniXelI BIOTECHNOLOGY:UniXelI BIOTECHNOLOGY is at the international forefront of R&D in cell therapy technologies for neurological disorders and is one of the few companies globally capable of researching, developing, and manufacturing iPSC-derived dopamine precursor cells. Shanghai Pudong Venture Investment Co., Ltd.’s decision to make a follow-on investment in UniXelI BIOTECHNOLOGY stems from its continued confidence in the company’s core innovative capabilities and long-term growth potential, demonstrating state-owned capital’s commitment to practicing"Patient Capital"Our philosophy and unwavering commitment to growing alongside outstanding sci-tech innovation enterprises. Cell and gene therapy is a key sector for long-term strategic investment by Shanghai Pudong Venture Investment Co., Ltd., and UniXelI BIOTECHNOLOGY’s core technology platform and R&D capabilities in the field of neurodegenerative diseases are highly aligned with this focus.Strategic Directions for Promoting High-Quality Development of the Stem Cell Industry in Pudong New AreaUnder the guidance of national strategy, Shanghai Pudong Venture Investment Co., Ltd. will continue to leverage its capital resilience and strategic patience to support outstanding enterprises like UniXelI BIOTECHNOLOGY in achieving steady and long-term growth, thereby injecting momentum into the high-quality development of the biopharmaceutical industry in Pudong and across China.

Fang Haiyan, Chief Operating Officer of UniXelI BIOTECHNOLOGY, stated“We extend our heartfelt gratitude to SSCILF and Shanghai Pudong Venture Investment Co., Ltd. for their steadfast support and profound trust in UniXelI BIOTECHNOLOGY! The successful completion of this financing round marks another crucial milestone in the development journey of UniXelI BIOTECHNOLOGY. Amid current market challenges, this achievement reflects the high recognition by both the government and capital markets of UniXelI’s technological prowess and R&D accomplishments, while also injecting confidence and vitality into the stem cell therapy industry. We will fully leverage the strong momentum from this financing to accelerate clinical trials of our core pipeline and actively expand our new R&D pipelines. Meanwhile, we will actively align with national policy guidelines promoting the high-quality development of the biopharmaceutical industry, further deepen collaborative partnerships with the government, enterprises, and all sectors of society, and strive to bring innovative cell therapy products to market at an early stage to benefit patients, thereby contributing to the innovative development of China’s biopharmaceutical industry.”

The successful completion of this financing round marks a significant milestone in the development journey of UniXelI BIOTECHNOLOGY. We sincerely appreciate the recognition and support from SSCILF and Shanghai Pudong Venture Investment Co., Ltd., as well as the strong assistance provided by financial advisors such as Taiyi Capital in this round. Seizing this opportunity, the Company will continue to expand its R&D pipeline, accelerate the clinical trial progress of its core products, and deepen strategic collaborations with leading institutions such as Shanghai Ruijin Hospital. We are committed to translating cutting-edge cell therapy achievements into tangible clinical value, thereby contributing positively to the development of the biopharmaceutical industry.